Previous Page Next Page

Characteristics

LOXO-195, a is a novel, selective and highly potent TRK inhibitor that is being initially developed for use in patients who have progressed or are intolerant to prior TRK inhibitor therapy [1-3]. BAY 2731954 (LOXO-195) can be dosed orally and twice daily [4].

References

  1. Blake J, Kolakowski GR, Tuch B et al. The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers. European Journal of Cancer 2016; 69: S144-S145.
  2. Drilon A, Nagasubramanian R, Blake JF et al. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. Cancer Discov 2017; 7: 963-972.
  3. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 2018; 15: 731-747.
  4. Hyman D, Kummar S, Farago A et al. Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi). Presented at: AACR Annual Meeting: March 29 to April 3, 2019; Atlanta, GA. Abstract CT127. 2019.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings